

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Denosumab for preventing skeletal-related events in multiple myeloma ID1233

Final matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Amgen (denosumab) <p><u>Patient/carer group</u></p> <ul style="list-style-type: none"> • Action on pain • Black Health Agency • Bloodwise • Cancer Black Care • Cancer Equality • Cancer52 • DKMS • HAWC • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Leukaemia Cancer Society • Leukaemia CARE • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Muslim Council of Britain • Myeloma UK • Pain Concern • Pain Relief Foundation • Pain UK • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • British Committee for Standards in Haematology • British Geriatrics Society • British Institute of Musculoskeletal Medicine 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (zoledronic acid, sodium clodronate) • Allergan (zoledronic acid, sodium clodronate) • Bayer (sodium clodronate) • Dr Reddy's Laboratories (zoledronic acid) • Hospira (zoledronic acid, disodium pamidronate) • Intrapharm Laboratories (zoledronic acid, sodium clodronate) • Kent Pharmaceuticals (zoledronic acid)

Provisional matrix for the single technology appraisal of denosumab for preventing skeletal-related events in multiple myeloma ID1233
Issue date: September 2017

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Orthopaedic Association • British Orthopaedic Oncology Society • British Psychosocial Oncology Society • British Society for Haematology • Cancer Research UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Health Forum • UK Myeloma Forum • UK Clinical Pharmacy Association • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Brent CCG • NHS England • NHS South Lincolnshire CCG • Welsh Government 	<ul style="list-style-type: none"> • Medac (zoledronic acid, disodium pamidronate) • Mylan (zoledronic acid) • Novartis Pharmaceuticals (zoledronic acid) • Peckforton Pharmaceuticals (zoledronic acid) • Sandoz (zoledronic acid) • Seacross Pharmaceuticals (zoledronic acid) • Sun Pharmaceuticals (zoledronic acid) • Teva (zoledronic acid) • Wockhardt (disodium pamidronate) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Bone Research Society • Cochrane Haematological Malignancies Group • Cochrane Musculoskeletal Group • Institute of Cancer Research • Leuka • Leukaemia Busters • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.